Clinical status and implications of antimalarial drug resistance

详细信息	查看全文 | 推荐本文 |

• 作者：Winstanley ; Peter A. ; Ward ; Steven A. ; Snow ; Robert W.
• 关键词：Falciparum malaria ; Drug resistance
• 刊名：Microbes and Infection
• 出版年：2002
• 期刊代码：65_12864579
• 类别：imm
• 出版时间：March, 2002
• 卷：4
• 期：3
• 页码：157-164
• 文件大小：92.2 K

摘要

Africa carries the greatest burden of disease caused by Plasmodium falciparum, and we can expect this burden to rise in the near future, mainly because of drug resistance. Although effective drugs are available (such as artemether–lumefantrine, mefloquine, atovaquone–proguanil and halofantrine) they are uniformly too expensive for routine use. Affordable options include chloroquine plus sulfadoxine–pyrimethamine (SP), amodiaquine (alone or in combination with SP) and chlorproguanil–dapsone. Artemisinin combination therapy may offer considerable advantages over alternative therapies, but its introduction faces considerable logistic difficulty.